Navigation Links
AlphaRx CEO Accumulates More Company Shares
Date:1/9/2008

MARKHAM, ON, Jan. 9 /PRNewswire-FirstCall/ - AlphaRx (OTC BB:ALRX - News) stated on Tuesday that CEO Michael Lee purchased 720,000 shares of AlphaRx Inc Common Stock in the open market, bringing the total number of shares purchased to 2,219,700 within the last 60 days, reflecting his continued confidence in the Company's future.

Mr. Michael Lee reported buying a total of 720,000 AlphaRx shares for an average price of $0.24 each, increasing his holdings to about 15,609,814 shares or 17.06% of the company, according to a filing with the Securities and Exchange Commission.

About AlphaRx Inc.

AlphaRx is a specialty pharmaceutical company utilizing proprietary site-specific nanoparticulate drug delivery systems to develop novel formulations of drugs that are insoluble or poorly soluble in water or have yet to be administrable to the human body with an acceptable delivery method. The Company also discovers and develops novel, small-molecule drugs for the treatment of inflammatory diseases and neurodegenerative diseases.

Forward Looking Statements:

This release contains forward-looking statements within the meaning and pursuant to the Safe Harbor provisions of the Securities Litigation Reform Act of 1995 and involve risks and uncertainties that may individually or mutually impact the matters herein described, including but not limited to product development and acceptance, manufacturing, competition, regulatory and/or other factors, which are outside the control of the companies.


'/>"/>
SOURCE AlphaRx Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. AlphaRx Officers and Directors To Exercise Options, Warrants and Retain Shares
2. AlphaRx Announces Debt Conversion
3. AlphaRx To Present at 47th Annual ICAAC
4. WellPoint Appoints Brian A. Sassi as President and CEO of the Companys Consumer Business Unit
5. New Colonial Life Brand Clarifies Companys Strengths
6. ForSight Labs, LLC Announces Formation of Its Third Company, ForSight VISION3, Inc. and Closing of $6 Million in Series A Funding
7. Perrigo Company to Present at The 26th Annual JPMorgan Healthcare Conference
8. KV Pharmaceutical Company Announces NYSE Listing Extension
9. Nevada company, ORNL develop potential lifesaver
10. Life Denied: California Nurses, Family of Sick Teen March on Health Insurance Company Thursday
11. Medicare Fraud Strike Force Cases Result in Long Prison Terms for Five Health Care Company Owners
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... PA (PRWEB) , ... May 05, 2016 , ... ... on long-acting injectables (LAIs), today announced a development collaboration with the ... to treat serious mental disorders such as schizophrenia. , LAI medicines can offer ...
(Date:5/5/2016)... Palm Beach, Fla. (PRWEB) , ... May 05, 2016 , ... ... Vision Institute in San Diego, California. The laser eye center will now be called ... recognized surgeons and attentive staff will remain at the full-service facility to ensure that ...
(Date:5/5/2016)... ... May 05, 2016 , ... LELO has discovered many people ... fans reach out via email, social media and on the Volonté blog seeking advice ... way I masturbate ‘normal’ or ‘correct’?” , While some methods are more common than ...
(Date:5/5/2016)... Fort Collins, CO (PRWEB) , ... May 05, ... ... has announced the commencement of a master charity program created to assist the ... every 60 days, working closely with nonprofit organizations and community leaders. Their hope ...
(Date:5/5/2016)... TX (PRWEB) , ... May 05, 2016 , ... Vitenas ... AIA/AAH Healthcare Design Awards, presented by the American Institute of Architects and the Academy ... designed by the renowned Perkins+Will and Harrell Architects, opened to patients in October of ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)... Research and Markets has ... Keratosis Market and Competitive Landscape Highlights - ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ... Highlights 2016, provides comprehensive insights into Actinic ... Keratosis market valuations and forecast, Actinic Keratosis ...
(Date:5/3/2016)... 4, 2016 Research and Markets ... Stem Cell Therapy Market Outlook 2020" report to ... ) , ,Recombinant technology has improved significantly in past ... be developed in coming years. Many cancer drugs have ... cell therapies are also expected to be developed with ...
(Date:5/3/2016)... 3, 2016   BIOTRONIK , a leader ... Food and Drug Administration (FDA) approval of Iperia ... heart failure patients with access to diagnostic magnetic ... remote monitoring with daily automatic transmission and closed ... in response to physiological demands. ...
Breaking Medicine Technology: